ABSTRACT Type 1 diabetes mellitus is a lifelong disease with very high morbidity, and its medical expenses are also very alarming. It not only seriously threatens the health of patients, but also brings heavy financial burden to their families. It is necessary to seek effective and low-cost diabetes treatment therapies. Currently, the existing artificial pancreas (AP) systems emphasize only on the blood glucose (BG) control performance. This paper attempts to reduce both the economic cost and the computational burden while guaranteeing the control performance in a bi-hormonal AP system. Since economic model predictive control (EMPC) could improve the economic profit and event-triggered control could save computational resources, they are integrated and then the integrated method is applied to the bi-hormonal AP. The proposed method achieves the desired objective: 1) it guarantees the control performance, i.e., BG is maintained within 70-180mg/dL, and the average tracking error and BG risk index are small enough (21.23 and 1.59); 2) it significantly reduces the economic cost, where the total price of the hormone is reduced by 67.15% compared with the switching PID and 56.22% compared with the switching MPC; and 3) it substantially improves the computational efficiency, where the running time is reduced by 51.14% compared with the switching EMPC. It also performs well in robustness tests. Future studies will involve the clinical evaluation of the proposed scheme.
I. INTRODUCTION
In recent years, the number of people with diabetes has increased dramatically, up to 415 million by the end of 2015 [1] . Type 1 diabetes mellitus (T1DM) is damaging people's health seriously, which can cause a lot of complications such as nephropathy, peripheral neuropathy, blindness, etc. A total of 5 million people died of diabetes in 2015 [1] . Additionally, diabetes brings serious financial burden to patients, most of them live in middle-income countries or low-income countries [1] . The Diabetes Atlas (seventh edition) shows that global diabetes treatment costs exceeded $673 billion in 2015 [1] . In this situation, more and more researchers pay attention to the blood glucose management of T1DM, some researchers come up with the concept of artificial pancreas (AP) [2] , which combines continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (CSII) and automatic control algorithm.
The blood glucose can be regulated by AP automatically, several automatic control algorithms have been used in AP successfully, e.g. proportional-integral-derivative (PID) [3] , model predictive control (MPC) [4] , learning-type model predictive control [5] , customized model predictive control [6] and so on. At present, all existing studies [7] - [11] about AP only consider control effect. Decreasing treatment costs is also important for people with diabetes. Additionally, glucose management falls within real-time control, so increasing computational efficiency is equally important. The above reasons promote us to design a new algorithm for AP to reduce both the economic cost and the computational burden while guaranteeing the control performance.
In the field of process control, an increasing number of researchers are considering economic model predictive control (EMPC) due to its excellent capability for maximizing process economic profit [12] , [13] . EMPC has a framework similar to that of conventional MPC, but improves economic performance by changing the formulation of the cost function. In this formulation, a general cost function replaces the MPC quadratic cost function to consider the economics of a process. However, the generality of the cost function also leads to the EMPC optimization problem having much higher computational complexity than the conventional MPC optimization problem, which reduces the computational efficiency of the control system.
The event-triggered control method is a non-uniform sampled control algorithm. Whether or not the control task is executed at each sampling time depends on whether the event triggering condition set in advance is satisfied, and the execution mode reasonably reduces the number of times the control task is executed. In the literature, event-triggered control [14] - [18] had been widely used to save communication, control and computational resources. These event-triggered control results inspired us to attempt to integrate EMPC and event-triggered control to improve the computational efficiency of the general EMPC.
In this paper, we refer to the combined EMPC and event-triggered control schemes as ET-EMPC and apply it to the bi-hormonal AP, in which there are three modesinsulin infusion mode, glucagon infusion mode, and zeroinput mode. We use the proposed ET-EMPC in the insulin infusion and glucagon infusion modes to determine the hormone delivery rate, then use the switching rules, based on the switching theory, to choose the appropriate mode to be applied at every sampling moment. We integrate EMPC and event-triggered control based on the concept presented by Zhang et al. [19] , who used event-triggered control to reduce the number of evaluations of the EMPC cost function. However, the core concept in our study, i.e., the design of the triggering condition, is very different from that in [19] . We design the triggering condition primarily based on the safe range of glucose levels.
To evaluate the proposed algorithm, we compared our method with the switching PID controller [3] and the switching MPC [4] on the standard subject, where our method owns great control performance, and the total price of hormone is reduced by 67.15% compared with the switching PID, 56.22% compared with the switching MPC. Then, we compared its performance with that of the switching EMPC to determine its effectiveness in increasing computational efficiency, where the running time is reduced by 51.14%. Next, we performed robustness tests with respect to meal variations, hormone sensitivity variations, and subject variability, where our method performs excellently.
To the authors' best knowledge, this study has the following contributions: 1. EMPC is used to design the insulin/glucagon infusion rates, and hence the treatment costs for the patients are reduced. 2. Event-triggered control is introduced to reduce the number of evaluations of the EMPC cost function, and hence computational resources are saved. 3. The combination of EMPC and event-triggered control is first implemented in the closed-loop control of artificial pancreas, and the in silico results validate the effectiveness of the proposed method.
II. VIRTUAL SUBJECT AND ARX MODEL
In this section, we introduce the virtual subject, which replaces the real patient in our simulation experiments. Then, we introduce the auto-regressive exogenous (ARX) model, which is the EMPC prediction model and used to design the triggering condition.
A. VIRTUAL SUBJECT
The virtual subject can be divided into four models: a meal model, an insulin model, a glucagon model, and a glucose model, each of which can be described by several ordinary differential readily available in the literature [3] , [20] - [25] . In this study, we selected the meal and glucose models from [23] , the insulin model from [24] , and the glucagon model from that proposed in [3] .
We used a total of ten virtual subjects in our simulation experiments, designated as the standard subject the one with the same parameters as those in [3] , [23] , and [24] and numbered the other nine, as constructed in [4] , as Subs. 1-9, respectively.
B. ARX MODEL
The first key step in the designing EMPC is identifying the prediction model. In this study, we selected the ARX model as the prediction model for both hormone infusion modes, i.e., the insulin and glucagon infusion modes, which approximates the relationship between insulin & glucose and glucagon & glucose, and is used to predict future glucose levels based on the hormone delivery rate in each hormone infusion mode. We conducted an open-loop experiment on the virtual subject to obtain the parameters of the ARX models, in which the hormone delivery rate has a step change, so we used a step-response identification method. The ARX model is shown in (1) below:
where z −1 is the backward shift operator, d is the time delay, w(t) denotes disturbances, t is the sample moment with a sample interval of 5 min, G(t + 1) is the output representing the glucose concentration, and I (t − d) is the input representing the insulin or glucagon delivery rate.
We can obtain the predictive output sequence of each hormone infusion mode based on the present moment:
From (1), we have:
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and based on (2) and (3), we know the following:
Introducing the following notation:
. . .
leads to the following:
where
From (6), we can obtain the future output, as follows:
Therefore, we know:
where N is the prediction horizon.
Based on the second formula in (5), we have the following:
By combining (9), (10), and (11), we can obtain the following:Ŷ
In fact, we can divide U (t) into three parts, where
T is the historical input change rate;
T is the future input change rate (M is the control prediction horizon) to be determined by solving an optimization problem, so is denoted as
and the remaining input variations are forced to be zero. Correspondingly, we can divide ϒ into three parts, as in the following:
In this case, we can express the output prediction as follows:
III. INTEGRATING ECONOMIC MODEL PREDICTIVE CONTROL AND EVENT-TRIGGERED CONTROL
In this section, we discuss the design of our proposed control algorithm. First, we introduce the EMPC design, which involves cost function design and its receding horizon optimization. Then, we describe the design of the event triggering condition, which is based on the glucose prediction obtained by (15) and the safe range of glucose. Next, we describe the switching rules we use to switch between the three modes, i.e., the insulin infusion mode (δ = 1), the glucagon infusion mode (δ = 2), and the zero-input mode (δ = 3). Lastly, we describe the implementation strategy of the overall control algorithm, which is a summary of the above three segments. Fig. 1 illustrates the framework of the overall control algorithm. 
A. EMPC DESIGN
A detailed overview of EMPC can be found in [26] . In this section, we describe the design of the cost function and its receding horizon optimization. As for the identification of the prediction model, that has been introduced in section 2.2. Differences between EMPC and conventional MPC embody in the formulation of the cost function, the economic cost function (not a quadratic cost function) is used directly in EMPC to improve economic profits of the process. In glucose management, the economic profit embody in usages of hormones. In the procedure of blood glucose control, the amount of insulin and glucagon reflects the economic cost of the control process, and the tracking effect of the input on the set value reflects the control performance of the process. In addition, we do not want excessive switching of the insulin or glucagon pump. Hence, we designed the economic cost function of each hormone infusion mode, as shown in (16):
In (16), the first term drives the glucose to track to the setpoint to guarantee the glucose control performance and the second term reduces the hormone usages to reduce treatment costs, where M is the control horizon;Ŷ (t + 1|t) denotes the predictive output sequence obtained by (15) ; Y R (t) is the setpoint sequence, the dimension of which remain the same to the prediction horizon; each element is 110;Î (t + j |t )
is the predictive input (insulin or glucagon); Î (t +j |t )
is the input change rate; and α i (i = 1, 2) is the penalty coefficient. To avoid the occurrence of extreme glucose values, we use (17) to constrain the inputs, where I lower is the lower bound of the predictive input, which we selected to be 0.18 U/h, and I upper is the upper bound, which we selected to be 24 U/h.
The difference of cost function form between EMPC and MPC makes traditional methods which suitable for MPC cost function optimization, such as quadratic programming, sequential quadratic programming and MATLAB toolbox, unable to realize the optimization of EMPC cost function. With respect to solving the receding horizon optimization problem of the cost function, an intelligent algorithm is a good choice, such as particle swarm optimization (PSO) [27] , genetic algorithm (GA) [28] , or ant colony optimization (ACO) [29] . In this study, we chose PSO to optimize the constrained cost function (combining (16) and (17)), and we obtain the predictive input sequence as follows:
where we implement only the first term I * (t |t ) and repeat the optimization in the next triggering moment.
B. DESIGN OF TRIGGERING CONDITION
At each sampling moment t, the control algorithm checks the triggering condition, then decides whether the optimization problem (18) should be solved again. In this study, the triggering condition of each hormone infusion mode is designed based on the predictive glucose and the safe range of glucose, which we formulated as follows: are the lower and upper limits of the safe range of glucose, which we selected to be 70 and 180, respectively; η i (i = 1, 2) is the threshold, determined either by experience or trial and error; t q is the last instant in time that the optimization problem (18) was solved; N 0 is the maximum number of sampling intervals that EMPC is allowed to operate in openloop, which we selected to be 6; is the sampling period mentioned in section 2.2. The triggering condition shows that if the next three predictive glucose levels based on the last optimal control input all fall in a small safe range, i.e.
, and the time interval between current moment and last triggering moment is smaller than 30 min, then s(t) = 0, the triggering condition is not satisfied and the last optimal control input should continue to be implemented; else then s(t) = 1, this denotes that the triggering condition is satisfied, and the optimization problem (18) should be re-solved.
C. SWITCHING RULES
As stated above, the control system consists of three modes: the insulin infusion mode, glucagon infusion mode, VOLUME 7, 2019 and zero-input mode, and we use switching rules to simulate the switching logic between them.
Similar to the EMPC cost function design, we designed the switching cost function as presented in (20) , which comprehensively considers the tracking error and economic cost, as follows:
where the same notations have the same meanings as in (16);
is the set-point, i.e., 110 mg/dL in this study; and M1 and N1 represent the control and prediction horizons, respectively, of the switching rules (
At every sample t, we can obtain the appropriate mode by comparing the three switching cost functions and choosing that with the lowest cost to work, as formulated in (21).
The whole implementation strategy for our proposed control algorithm is as follows:
1) Conduct an open-loop experiment on the virtual subject to identify the parameters of the ARX models. 2) At the first sampling moment, use EMPC in each hormone infusion mode to calculate the optimal control input, respectively. Let t q := 1. 3) Beginning from the second sampling moment, at every sample t, use (15) to calculate the glucose prediction, i.e.,ŷ(t +i|t)| 3 i=1 , based on the last optimal control input in each hormone infusion mode. The EMPC of each hormone infusion mode checks the triggering condition. If it is satisfied, go to Step 4; else, implement the last optimal control input again and go to Step 5. 4) Re-solve the optimization problem (18) and implement the new optimal control input. Let t q := t. 5) Use (20) to compute the switching cost functions of the three modes, then solve (21) to choose the appropriate working mode. 6) At the next sampling moment t + 1, go to Step 3.
IV. EXPERIMENTAL RESULTS AND DISCUSSION
In this section, we first introduce our experimental design and then present our experimental results for the standard subject, in which we compare the results of our proposed switching ET-EMPC with those of the switching PID [3] and switching MPC [4] . Next, to demonstrate the effectiveness of the event-triggered method in reducing the computational time, we compare the results of the switching ET-EMPC and switching EMPC. There are many interfering factors in the daily blood glucose regulation of real diabetics. A blood glucose regulation control algorithm with clinical significance must be robust to a variety of disturbances. It is meaningful to carry out the necessary robustness test. In Subsections 4.4, 4.5, and 4.6, we describe our robustness test results regarding meal variations, hormone sensitivity variations, and subject variability, respectively.
A. EXPERIMENT DESIGN
First, to obtain the parameters of two ARX models, we conducted two 12-hour open-loop experiments on the virtual subject without meals. We derived the ARX model of the insulin infusion mode during the first 12-hour experiment and that of the glucagon infusion mode in the second 12-hour experiment, using the model identification toolbox in MATLAB, as expressed by (22) and (23), respectively.
Then in the closed-loop simulation experiment, we assumed that the subject eats three meals every day at 7:00, 12:00, and 18:00, respectively, and the amount of carbohydrates consumed are 40g, 60g, and 85g, respectively. We set the glucose set-point to 110 mg/dL and the safe range of glucose as 70-180 mg/dL.
B. EXPERIMENT ON THE STANDARD SUBJECT
In this section, we apply the proposed switching ET-EMPC and the other two methods, the switching PID [3] and switching MPC [4] , to the standard subject, in turn. Their control profiles are shown in Fig. 2-4 , respectively. In each figure, the sub-figures (a), (b), and (c) show the glucose levels, the insulin delivery rate, and the glucagon delivery rate on the second day, respectively. Tables 1 and 2 provide statistical data on the control performance and economic cost associated with the second day, respectively. In Table 1 , we used the average tracking error (ATE), calculated using (24), to reflect the tracking performance and used the blood glucose risk index (BGRI) [30] to reflect BG fluctuation and risk. Table 2 provides the total price of hormone used in control to reflect the economic cost, where the unit price of the insulin is 0.3 yuan/U and the unit price of the glucagon is 1 yuan/U. The unit price here is in line with the actual situation, and we use it to get a more intuitive comparison.
where G(t) is the real glucose output; y r is the set point, which is set to 110mg/dL in this study; T is the number of samplings in one day, this paper is set to 288. Table 1 indicate the control performance of the switching ET-EMPC is better than that of the switching PID [3] and similar to that of the switching MPC [4] . 
TABLE 2.
Statistical data on the economic costs of the switching ET-EMPC, switching PID [3] , and switching MPC [4] .
As statistical data shown in Table 2 , the switching ET-EMPC clearly demonstrated its ability to reduce the associated economic cost. As such, we can confirm the success of the switching ET-EMPC design, having achieved our goal to reduce economic cost while guaranteeing good control performance.
C. IMPROVED COMPUTATIONAL EFFICIENCY
As shown in section 4.2, the proposed ET-EMPC can effectively reduce the economic cost, due to the use of EMPC. As such, why don't we use the EMPC directly? Because the computational complexity of the EMPC is typically much higher than other optimization algorithms due to the generality of its cost function, which increases the computational time of the whole system. Since glucose management is a real-time application, it is important to guarantee the computational efficiency of the control actions. In this study, we added the event-triggered method to the general EMPC to create the ET-EMPC to increase computational efficiency by reducing the number of EMPC cost function evaluations. To demonstrate the effectiveness of the proposed method in reducing the computational burden, we compared the switching ET-EMPC with the switching EMPC alone. To guarantee a fair comparison, we removed only the triggering condition from the switching ET-EMPC to create the switching EMPC, retained all the same parameters for both, and conducted the experiments on the same computer under the same conditions. Fig. 5 shows the control profiles and Table 3 provides the relevant statistical results. In Table 3 , the running time is the average value of the 100 simulation experiments. Table 3 show that the control performance of the switching ET-EMPC is slightly lower than that of the switching EMPC, although its economic cost is slightly better. Overall, we can say that the performance of the switching ET-EMPC is similar to that of the switching EMPC. In this paper, we take the CPU running time as an index of the computational efficiency of the relevant control algorithms. As shown in Table 3 , the running time is 304.56 s for the switching ET-EMPC and 613.08 s for the switching EMPC. Compared with the switching EMPC, the proposed algorithm reduced the running time by 51.14%, which validates its effectiveness in improving computational efficiency. Although the running time of the proposed algorithm is slightly longer than those of the switching PID [3] and switching MPC [4] , it is acceptable for glucose control in real life.
D. ROBUSTNESS TESTS FOR MEAL VARIATIONS
Variations in meal sizes and times occur frequently in real life and an effective algorithm must perform effectively despite these variations. Hence, we performed robustness tests with respect to meal variations. First, we considered meal size variations of ±50% and meal time variations of ±40 min independently and then in combination. We realized meal variations by adding a uniformly distributed random variable to the normal meal size or meal time. Fig. 6 shows the resulting control profiles which drew by the average value of 100 Monte Carlo simulations. In Table 4 , the value outside the brackets is the average value of 100 Monte Carlo simulations, and the value in the brackets is the standard deviation of 100 Monte Carlo simulations. Table 4 demonstrate the good performance of the switching ET-EMPC when meal variations occur. The standard deviation in Table 4 indicate that the fluctuation of the running results is not very violent.
E. ROBUSTNESS TESTS ON HORMONE SENSITIVITY VARIATIONS
In real life, the hormone sensitivity of an individual subject could be time-varying due to exercise, stress, or other factors. As such, it is necessary to test the robustness of the switching ET-EMPC with respect to hormone sensitivity. In this study, we indirectly changed the hormone sensitivity by multiplying a gain on the input of each hormone infusion mode, as shown below:Ĩ (t) = θ (t)I (t) (25) where I(t) is the hormone delivery rate during each hormone infusion mode;Ĩ (t) is the hormone's real influence on the human body; and θ (t) is the hormone sensitivity gain, uniformly distributed within [0.8 1.2], i.e., the hormone variations ranged between ±20%. Fig. 7 shows the resulting control profiles which drew by the average value of 100 Monte Carlo simulations. In Table 5 , the value outside the brackets is the average value of 100 Monte Carlo simulations, and the value in the brackets is the standard deviation of 100 Monte Carlo simulations. Table 5 verify that the switching ET-EMPC has excellent robustness with respect to hormone sensitivity variations. The standard deviation in Table 5 indicate that the fluctuation of the running results is not very violent.
F. ROBUSTNESS TESTS ON SUBJECT VARIABILITY
The differences between individuals represent a great challenge in biomedical control technologies. Superior performance must be demonstrated across a range of subjects for the results to be appropriate for general application. As such, we performed robustness tests with respect to subject variability. In this section, we describe our tests of the proposed switching ET-EMPC on ten different subjects, i.e., the standard subject and Subs. 1-9 mentioned in section 2.1. These subjects have different model parameters and different hormone sensitivities, and thus have subject-specific ARX models. To increase the adaptive ability of the proposed algorithm, we based the weights of the input penalty and input variation penalty on the parameters of the subjectspecific ARX models. In ( b i imply higher hormone sensitivity. As such, larger input penalty and input variation penalty weights must be chosen for this situation. In this study, m = 0 and b0 = −0.0044 in the insulin infusion mode for the standard subject and 0.0236 for the glucagon infusion mode. Therefore, we designed the penalty weights of the insulin and glucagon infusion modes for the i-th subject as shown in (26) and (27) , respectively. Fig. 8 shows the median and interquartile ranges of the glucose responses for the ten different subjects under the switching ET-EMPC, which reflects their overall glucose levels. Fig. 9 provides a visualization of the control-variability grid analysis (CVGA) [31] results regarding the quality of the proposed algorithm for the different subjects. In Fig. 8 , we see that the overall glucose responses of the ten different subjects are acceptable, whereby only four subjects experienced transient hypoglycemia and only two experienced transient hypoglycemia. In Fig. 9 , all points are located in zones A + B. These results clearly demonstrate the VOLUME 7, 2019 FIGURE 9. Control-variability grid analysis (CVGA) results of ten subjects under the switching ET-EMPC. excellent robustness of the proposed algorithm with respect to subject variability.
V. CONCLUSION
In this study, we integrated the economic model predictive control and event-triggered control to create the ET-EMPC, and also added switching rules to control glucose in the bi-hormone artificial pancreas system. Our experimental results show that the proposed method can guarantee control performance and reduce economic cost while increasing computational efficiency. In addition, the switching ET-EMPC demonstrated excellent robustness to meal and hormone sensitivity variations and a superior adaptive ability to subject variability. Future work will involve clinical evaluation of the proposed scheme. Her research interests include multi-agent system, fault-tolerant control, and fault diagnosis and isolation. VOLUME 7, 2019 
